@article{40c5c2b0ea8a402d9254e2ae6cb42f98,
title = "The ATN Framework-Moving Preclinical Alzheimer Disease to Clinical Relevance",
author = "{van der Flier}, {Wiesje M.} and Philip Scheltens",
note = "Funding Information: reported part-time employment with EQT Life Sciences, grants from the Alzheimer's Drug Discovery Foundation and Cure Alzheimer, support Funding Information: Alzheimer Nederland, Hersenstichting, CardioVascular Onderzoek Nederland, Philips, Life-MI, AVID, Biogen MA Inc, Roche BV, Novartis NL, Fujifilm, Combinostics, Pasman Stichting, Stichting Dioraphte, Gieskes-Strijbisfonds, Stichting Equilibrio, and Edwin Bouw Fonds. She is also a recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP allowance; #LSHM20106). All funding for this is paid to her institution. She has performed contract research for Biogen MA Inc and Boehringer Ingelheim, been an invited speaker at Boehringer Ingelheim, Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape), and Springer Healthcare, is a consultant to Oxford Health Policy Forum CIC, Roche, and Biogen MA Inc, and participated in advisory boards of Biogen MA Inc and Roche. All funding for these is paid to her institution. She is also a member of the steering committee of PAVE and Think Brain Health, associate editor of Alzheimer, Research & Therapy in 2020/2021, and associate editor at Brain.",
year = "2022",
month = oct,
day = "1",
doi = "https://doi.org/10.1001/jamaneurol.2022.2967",
language = "English",
volume = "79",
pages = "968--970",
journal = "JAMA Neurology",
issn = "2168-6149",
publisher = "American Medical Association",
number = "10",
}